Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding: 2014-2023

Historic Shares Outstanding for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2023 value amounting to $36.1 million.

  • Spyre Therapeutics' Shares Outstanding rose 1169.35% to $51.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $51.4 million, marking a year-over-year increase of 1169.35%. This contributed to the annual value of $36.1 million for FY2023, which is 1279.38% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Shares Outstanding of $36.1 million as of FY2023, which was up 1,279.38% from $2.6 million recorded in FY2022.
  • Over the past 5 years, Spyre Therapeutics' Shares Outstanding peaked at $48.0 million during FY2020, and registered a low of $2.0 million during FY2021.
  • For the 3-year period, Spyre Therapeutics' Shares Outstanding averaged around $13.5 million, with its median value being $2.6 million (2022).
  • Per our database at Business Quant, Spyre Therapeutics' Shares Outstanding tumbled by 95.88% in 2021 and then skyrocketed by 1,279.38% in 2023.
  • Spyre Therapeutics' Shares Outstanding (Yearly) stood at $29.1 million in 2019, then skyrocketed by 64.90% to $48.0 million in 2020, then slumped by 95.88% to $2.0 million in 2021, then skyrocketed by 32.42% to $2.6 million in 2022, then spiked by 1,279.38% to $36.1 million in 2023.